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Abstract: Epinephrine is the only medication recommended by the International Liaison Committee
on Resuscitation for use in newborn resuscitation. Strong evidence from large clinical trials is lacking
owing to the infrequent use of epinephrine during neonatal resuscitation. Current recommendations
are weak as they are extrapolated from animal models or pediatric and adult studies that do not
adequately depict the transitioning circulation and fluid-filled lungs of the newborn in the delivery
room. Many gaps in knowledge including the optimal dosing, best route and timing of epinephrine
administration warrant further studies. Experiments on a well-established ovine model of perinatal
asphyxial cardiac arrest closely mimicking the newborn infant provide important information that
can guide future clinical trials.
Keywords: resuscitation; epinephrine; newborn; intravenous; intraosseous; intramuscular
1. Introduction
The infrequent need for chest compressions and epinephrine use during neonatal resuscitation [1,2],
coupled with an inability to consistently anticipate which newborns are at high risk of requiring
extensive resuscitation, explains the ongoing lack of high quality evidence supported by large
randomized clinical trials to better guide healthcare providers in their resuscitative efforts. The current
understanding and knowledge of resuscitative medicine in newborns is further limited by animal
and simulation models that do not adequately depict the transitioning fetal circulation, fluid-filled
alveoli and patent ductus arteriosus inherent to newborn infants [3–5]. Furthermore, the underlying
etiology of bradycardia, and ultimately cardiac arrest, in neonates, as a result of severe hypoxemia,
metabolic acidosis and vascular compromise, contrasts that which is most commonly observed in
adults, where the abrupt cessation of cardiac output in the setting of well-oxygenated blood follows
the onset of arrhythmias. The current recommendations guiding neonatal resuscitation with regard to
chest compressions and epinephrine administration are largely extrapolated from studies compromised
by the aforementioned limitations. Additional studies evaluating chest compressions and epinephrine
in a model with transitioning physiology and fluid-filled lungs may potentially impact the use of these
interventions [6].
Severely asphyxiated neonates with extreme bradycardia or cardiac arrest who have been
successfully resuscitated following chest compressions and (or) epinephrine administration are at
greater risk of severe neurologic impairment [7–9]. While the ultimate goal of resuscitative efforts
is to swiftly establish the return of spontaneous circulation (ROSC), assuring adequate perfusion to
vital organs by means of efficient chest compressions and vasoactive drug administration are likely
to improve intact survival. Epinephrine is the only medication currently recommended for neonatal
resuscitation by the International Liaison Committee on Resuscitation (ILCOR) [10–12]. The optimal
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timing, route and dose of epinephrine administration in neonatal resuscitation, however, has not been
established. In the following review, a brief summary on the evidence of epinephrine use in neonatal
resuscitation, as well as data from emerging translational studies from an ovine model of transitioning
physiology and fluid-filled lungs is presented. We also reviewed the current understanding of dose,
route and efficacy of epinephrine and alternate medications that have been investigated for neonatal
bradycardia and cardiac arrest.
2. A Brief History on Coronary Perfusion Pressure and Epinephrine
In the late 19th century, physiologic research showed that the excised heart could beat again when
the coronary arteries were subjected to a considerable pressure from some circulating medium [13].
During the same period, scientists studying the physiologic effects of an isolated substance (later
termed epinephrine also known as adrenaline [14]) from the suprarenal capsules (adrenal glands)
demonstrated significant increases in heart rate and blood-pressure following its intravenous (IV)
administration in experimental dogs [15]. Following the discovery of epinephrine’s pharmacologic
effects and recognizing the importance coronary pressures play in reviving the heart, the value of
administering epinephrine to raise coronary pressures was soon appreciated. The use of epinephrine
did not become clinically widespread until the 1960s, however, breakthrough experiments by Redding
and colleagues demonstrated a significant improvement in rates of ROSC with the administration of
IV epinephrine in a canine model of asphyxia-induced cardiac arrest [16].
Catecholamines mediate their cardiovascular actions predominantly through α1, β1, β2, and
dopaminergic receptors, the density and proportion of which modulate the physiological responses
in individual tissues [17]. Epinephrine is an endogenous catecholamine with high affinity for α1, β1,
and β2-receptors present in cardiac and vascular smooth muscle (Figure 1). Experimental studies
in asphyxiated dogs pretreated with α-adrenergic inhibition (phenoxybenzamine) or β-adrenergic
inhibition (propranolol) have demonstrated that α-adrenergic stimulation by epinephrine likely
explains its mechanism of action [18], and epinephrine’s vasoconstrictive properties are primarily
responsible for its effectiveness in achieving ROSC [19].
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Figure 1. Coronary perfusion pressure (CPP) and the mechanism of action of epinephrine. CPP is 
calculated as the difference between the aortic diastolic pressure and the right atrial pressure serves 
as a surrogate to coronary blood flow. In the premature infant, the effect of a left to right (from aorta 
into pulmonary artery) flow on coronary blood flow is unknown. Epinephrine’s effect on 
alpha-adrenergic receptors on peripheral vasculature leads to vessel contraction and a rise in 
systemic vascular resistance that can increase CPP. Epinephrine also exerts stimulation of 
beta-adrenergic receptors on myocytes that increase cardiac contractility. α: Alpha; β: Beta; LV: Left 
ventricle; PA: Pulmonary artery; PDA: Patent ductus arteriosus. Copyright Satyan 
Lakshminruismha. 
Figure 1. Coronary perfusion pressure (CPP) and the mechanism of action of epinephrine. CPP is
calculated as the difference between the aortic diastolic pressure and the right atrial pressure serves as
a surrogate to coronary blood flow. In the premature infant, the effect of a left to right (from aorta into
pulmonary artery) flow on or nary blood flow is nknown. Epinephrine’s effect on lpha-adrenergic
receptors on peripheral vasculature leads to vessel contraction and a rise in systemic vascular resistance
that can increase CPP. Epinephrine also exerts stimulation of beta-adrenergic receptors on myocytes
that increase cardiac contractility. α: Alpha; β: Beta; LV: Left ventricle; PA: Pulmonary artery; PDA:
Patent ductus arteriosus. Copyright Satyan Lakshminruismha.
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3. Epinephrine in Neonatal Resuscitation
In the asphyxiated, severely acidotic state, the newborn is likely to be maximally vasodilated
with very low systemic vascular resistance (SVR). Administration of epinephrine is believed to induce
intense peripheral vasoconstriction resulting in elevated SVR and an increase in coronary perfusion
pressure (CPP) to improve coronary blood flow [2,20]. However, in severely acidotic lambs (by infusion
of lactic acidosis), hemodynamically compromised through hypoxemia, intravenous epinephrine
administration at 0.01 mg/kg did not improve cardiac output, heart rate or blood pressures [21]. Not only
is the efficacy of epinephrine use in neonatal resuscitation poorly understood, the optimal timing, dose
and route, and the potential adverse effects of epinephrine administration remain largely unknown.
Intravenous (IV) administration of epinephrine is preferred as it provides 100% bioavailability.
Alternate routes of drug administration have been described as early as 1913 through an endotracheal
tube (ETT) [22] or an intraosseous (IO) device, first reported in the literature in 1916 [23], and
by intramuscular (IM) injections (a common route during anaphylaxis) (Figure 2). The current
recommended epinephrine dose by the neonatal resuscitation program (NRP) is 0.01–0.03 mg/kg IV or
IO and 0.05–0.1 mg/kg through the ETT [24].
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3.1. Intravenous Epinephrine
In their cani e model of asph i l c r iac-arrest model, the authors reported greater success
of ROSC compar t llo ing administration of epinephrine at 1 mg [16]. Clinical
studies following this report did not ac ount f i ht difference and showed th return of
spontaneous circulation at the same dose (i.e., ≈ 0.01–0. 15 mg/kg, assuming an adult weight of 70 kg),
which was then extrapolated to neonatal and pediatric patients with dose ranges of 0.01–0.03 mg/kg.
High-dose IV epinephrine (0.1–0.2 mg/kg) in newborn and pediatric animal models has been shown to
be associated with severe tachycardia, hypertension, reduced stroke volume and cardiac output, and
higher mortality in the immediate post-resuscitation period [25,26]. The strongest evidence regarding
high- or low-dose epinephrine comes from a randomized clinical study of in-hospital pediatric cardiac
arrest. Following a first standard-dose of epinephrine at 0.01 mg/kg IV, 68 patients were randomized
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to receive subsequent doses of either 0.1 mg/kg or 0.01 mg/kg. Success in ROSC was similar between
groups (20/34 and 21/34, respectively), however there were no survivors in the patients randomized to
high-dose epinephrine compared to 4/34 (12%) in the low-dose group [27]. Furthermore, among the
30 patients with asphyxial cardiac arrest, 7/18 patients randomized to low-dose epinephrine survived,
whereas none of the 12 patients randomized to high-dose epinephrine survived to hospital discharge.
The American Heart Association currently dissuades the use of high-dose IV epinephrine in adult
cardiac arrest [28].
Low Umbilical Venous Catheter
Placement of a low UVC (2–4 cm from the umbilical stump) is an effective and efficient mode
of securing IV access in the delivery room. The bioavailability and plasma concentrations achieved
with administration of epinephrine by this route are similar to that of epinephrine delivered via a
central venous catheter. The umbilical vein joins the left branch of the portal vein and eventually drains
through the ductus venosus in to the inferior vena cava. Animal experiments demonstrate that 50% of
umbilical blood flow is shunted through the ductus venosus. During hypoxemia, the shunted fraction
could reach 70%, especially when associated with hypovolemia. In human fetuses, the shunted fraction
is 28–32% at 18–20 weeks gestation, 22% at 25 weeks and 18% at 31 weeks. Based on the concept of the
“via sinistra” pathway, blood is preferentially streamed across the oval foramen to the left atrium, left
ventricle, ascending aorta and coronary circuit [29]. It is likely that epinephrine administered through
a UVC enters the left side of the heart through the patent foramen ovale subsequently accessing the
systemic circulation (and coronary circulation). Thus, epinephrine administered by this route bypasses
the liver and is not subject to hepatic metabolism (Figure 3).
Epinephrine administration by a low umbilical venous route has several advantages and is the
preferred route as per NRP recommendations; these advantages include:
• Ease of placement by trained resuscitators
• 100% bioavailability
• Bypass of hepatic metabolism if drug enters inferior vena cava through the ductus venosus.
• Access to the systemic circulation through an oval foramen and bypass of the lung
• Efficacy in clinical and translational studies
• Benefit of venous access for the administration of volume bolus (including transfusion of packed
red blood cells) and blood sampling.
There are some drawbacks of umbilical venous epinephrine; these include:
• Placement of the catheter requires training. Adult providers such as emergency medical technicians
are often uncomfortable placing an umbilical venous catheter.
• Access to a sterile catheter and insertion equipment is necessary.
• Complications of deep placement in a branch of the portal vein can include hepatic ischemia and
possibly necrosis.
• Placement can be challenging. The ductus venosus has some inherent resistance in the absence of
blood flow (as in cardiac arrest) and this resistance needs to be overcome with adequate volume
of flush following administration of epinephrine.
• Attempts to place a UVC can interfere with the delivery of effective chest compressions. This can
be overcome by delivering chest compressions from the head-end of the radiant warmer.
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Figure 3. Causes for poor bioavailability and efficacy of epinephrine administered through a low
umbilical venous catheter (UVC). The internal volume of a 5 Fr UVC with a stopcock is 0.55 mL. A flush
of 0.5–1 mL will clear the catheter and deposit epinephrine in the umbilical vein. In the presence of
adequate pressure and flow into the umbilical vein, 40–50% of administered fluid passes through the
ductus venosus [30]. In the absence of umbilical flow (as in cardiac arrest), the inlet of the ductus
venosus narrows. The terminal portion of the inferior vena cava and ductus venosus do not have
valves and backpressure from chest compressions can potentially cause back-flow. Epinephrine also
increases portal venous resistance. The liver is also a major site of epinephrine breakdown. Right atrial
delivery of a vasopressor can be enhanced by (a) catheter placement in the right atrium (not feasible in
the delivery room); (b) quick flush with a mini-bolus to open up the ductus venosus and enhanced
delivery to the heart in the absence of spontaneous circulation. Copyright Satyan Lakshminrusimha.
3.2. Endotracheal Epinephrine
IV access is not always readily available. In a simulation study to assess timing of epinephrine dose,
time to place an umbilical venous catheter (UVC) took a mean of 6 min compared to a mean intubation
time of less than 2 min [31]. Therefore, while intravenous access is attempted, NRP recommends
giving epinephrine through the ETT as an alternative route. In a retrospective study evaluating the
efficacy of ETT epinephrine in the delivery room (at a time when the recommended dose was 0.01–0.03
mg/kg), 94% (44/47) of newborns requiring cardiopulmonary resuscitation (CPR) received the first
dose via ETT with a ROSC success of only 32% (14/44) [1]. In a more recent retrospective study,
only 20% (6/30) of newborns in the delivery room who received ETT epinephrine at a dose of 0.03 or
0.05 mg/kg achieved ROSC, while 71% (17/24) were subsequently successfully resuscitated following
IV epinephrine administration [32–34].
The high frequency of initial ETT epinephrine use in clinical practice makes it imperative that the
recommended dose be as effective as possible. In a newborn piglet model with induced ventricular
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fibrillation (VF), there was no significant increase in plasma epinephrine concentration as compared to
normal saline controls following ETT epinephrine at a dose of 0.01 mg/kg [35]. Similarly, in an adult
swine model of VF, administration of epinephrine by ETT at 0.01 mg/kg did not result in any meaningful
rise in epinephrine plasma concentrations compared to normal saline control animals, whereas ETT
epinephrine at 0.1 mg/kg resulted in concentrations of 215 ± 40 ng/mL with repeat ETT dosing doubling
the concentration to 402 ± 80 ng/mL [36]. Interestingly, instillation of ETT epinephrine at 0.1 mg/kg in
isolated rabbit lung models has shown a decreased effect on the pulmonary vascular response and
lower epinephrine concentrations in lungs isolated from rabbits aged 1 to 3 days compared to those
aged 14 to 21 days [37]. The presence of thicker vascular and alveolar walls in the newborn favors
using a higher dose of ETT epinephrine.
Recently, experiments in newborn lambs with transitioning fetal circulation and fluid-filled lungs
that closely mimic hemodynamically compromised newborns in the delivery room have proven helpful
in better understanding the effects and pharmacokinetics of epinephrine in neonatal resuscitation [38]
(Figure 4). In this perinatal asphyxial cardiac arrest lamb model, ETT epinephrine administration at
0.1 mg/kg resulted in delayed and lower peak plasma epinephrine concentrations (130 ± 60 ng/mL at
five minutes) compared to IV epinephrine administration at 0.03 mg/kg (≈ 460 ± 210 ng/mL at one
minute). The epinephrine concentration following ETT epinephrine was also considerably lower than
the values reported by the aforementioned study on adult swine [36]. This would be expected as
several limitations, particularly in the newborn, may decrease epinephrine absorption from the lungs:
(1) The fluid-filled lungs may dilute the drug, (2) high pulmonary vascular resistance and extracardiac
shunts decrease pulmonary blood flow, (3) the epithelial linings of the respiratory bronchi, alveoli, and
pulmonary capillaries are relatively thick at birth, and (4) epinephrine may cause local pulmonary
vasoconstriction limiting its own absorption [39]. Success of ROSC was also lower in the ETT group
(12/22 or 55%) compared to the intravenous group (19/22 or 86%). Seven lambs in the ETT group that
did not initially achieve ROSC were successfully resuscitated following IV epinephrine. The limited
absorption of ETT epinephrine also highlights the fundamental principle of newborn resuscitation:
Ventilation and achieving adequate functional residual capacity (FRC). Pulmonary vascular resistance
(PVR) is minimal at FRC [40]. Progressive increases in mean airway pressure towards total lung
volume reduces cardiac output by decreasing venous return and compressing alveolar pulmonary
vessels. Underinflated lungs may kink extra-alveolar pulmonary vessels and increase PVR. Achieving
an optimal FRC during ventilation maximizes pulmonary blood flow and may enhance absorption of
endotracheal epinephrine.
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Figure 4. Endotracheal epinephrine. Asphyxia and acidosis decrease systemic vascular resistance by
dilating the peripheral vascular bed, and high fetal pulmonary vascular resistance may lead to right
to left shunting at the PDA limiting pulmonary blood flow. The presence of fetal lung liquid may
dilute tracheal epinephrine, and absorption is further co promised by low pulmonary blood flow.
The dashed green line represents the proposed path of intratracheal epinephrine. A higher dose of
endotracheal epinephrine may compensate f r il ti f l ng liquid and overcome the diffusion
barrier to achieve hig er plasma con e trations. LV: Left ventricle; PA: ulmonary artery; PDA: Patent
ductus arteriosus; PVR: Pulmonary vascular resistance. Copyright Satyan Lakshminrus mha.
3.3. Intraosseous Epinephrine
Neonatal and pediatric resuscitation guidelines reco end IO epinephrine administration in
cases where IV access is uns ccessful [24,41]. In a eo atal simulation study, insertion of an IO device
was quicker by a mean of 46 s conds compared t placement of a UVC [42]. The medullary space in the
epiphyseal plat of long bones has a rich blood supply, which remains well pe fused during shock and
hypote sion [43]. A ult and animal pharmacokinetic studies have shown equivalent pharmacokinetics
comparing IV to IO drug administr t on [44,45]. Animal studies report contradicting results about
pharmacokinetics and plasma availability f IO epinephrine d inistration [46,47]. In a porcine model
of cardiac arrest, peak epinephrine concentrations were achieved quicker following IV administration
(78 ± 69 sec) compared to IO administration (156 ± 13 sec) [47]. In a noncardiac arrest lamb model,
a similar linear increase and comparable peak plasma epinephrine concentrations have been observed
following IO and IV administration [46]. Several cases of IO epinephrine administration in neonates,
including extreme premature infants have been reported in the literature with success in achieving
ROSC [48–51]. There are several different IO devices available, including manual and semi-automatic
types (e.g., Cook intraosseous needle [Cook Medical, Bloomington, IN, USA], EZ-IO [Telefex Medical,
Toronto, Canada]) [52]. IO epinephrine, therefore, may be a superior alternative to ETT epinephrine
when IV access is difficult or the skillset for UVC insertion is lacking. The efficacy of IO epinephrine in
the context of transitional physiology and asphyxia, however, needs further study (Figure 5).
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Obtaining IV, IO and (or) ETT access can often be challenging and requires an advanced skillset 
by medical caregivers. IM injection, however, is a simple procedure that can be performed by a 
layperson. IM epinephrine is well established as the initial treatment of choice for systemic 
anaphylaxis [53]. The ease of IM epinephrine injections offers a potential alternate route of 
epinephrine administration for newborn resuscitation, particularly in less resourced environments 
where obtaining IV or IO access may be more difficult. The literature on the use of IM epinephrine 
for resuscitation is sparse. In a pilot study in a swine model of cardiac arrest, IM epinephrine (0.1 
mg/kg) compared to IV epinephrine (0.01 mg/kg) demonstrated a comparable success in achieving 
ROSC [54]. However, no data on pharmacokinetics and plasma epinephrine concentrations were 
reported. There are currently no studies evaluating epinephrine absorption following IM 
administration in newborn resuscitation. In a lamb model of perinatal asphyxia cardiac arrest, 
Figure 5. X-ray showing distribution following (A) low-lying umbilical venous catheter or (B) tibial
IO administration of contrast in a perinatal cardiac arrested lamb model following 30 sec of chest
compressions. Rapid distribution of contrast into the venous vasculature and heart can be appreciated
following IO administration. IO: Intraossesus. Copyright Satyan Lakshminrusimha.
3.4. Intramuscular Epinephrine
Obtaining IV, IO and (or) ETT access can often be challenging and requires an advanced skillset by
medical caregivers. IM injection, however, is a simple procedure that can be performed by a layperson.
IM epinep rine is well established as the initial treatment of choice for systemic anaphylaxis [53].
The ease of IM epinephrine injections offers a potential alternate route of epinephrine administration
for newborn resuscitation, particularly in less resourced environments where obtaining IV or IO access
may be more difficult. The literature on the use of IM epinephrine for resuscitation is sparse. In a pilot
study in a swine model of cardiac arrest, IM epinephrine (0.1 mg/kg) compared to IV epinephrine
(0.01 mg/kg) emonstrated a comparable success in achieving ROSC [54]. However, no data on
pharmacokinetics and plasma epinephrine concentrations were reported. There are currently no
studies evaluating epinephrine absorption following IM administration in newborn resuscitation. In a
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lamb model of perinatal asphyxia cardiac arrest, pharmacokinetic data from two lambs that were
given IM epinephrine (0.1 mg/kg) in the deltoid muscle revealed that there was no significant rise in
plasma epinephrine concentration. In a state of complete circulatory arrest and severe acidosis, chest
compressions may not provide adequate perfusion to the muscles to circulate epinephrine deposited in
the muscle. Future studies assessing the efficacy of IM epinephrine in a model of profound bradycardia
(as opposed to asystole) are warranted.
3.5. Efficacy of Epinephrine and Adverse Effects
The evidence on the efficacy of epinephrine in neonatal resuscitation is inconsistent owing
to the heterogeneity of experimental models that differ in the species studied (dogs, piglets and
lambs), the definition used for cardiac arrest (asystole or predefined hypotension/bradycardia), and
the timing of epinephrine administration. The effects of epinephrine and chest compressions in
asphyxia models [55–65] characterized by profound acidosis and hypoperfusion cannot easily be
compared to VF models. Furthermore, animal asphyxia models wherein resuscitation is initiated
following cardiac arrest (asystole) [60–65], as opposed to after a predetermined drop in heart rate or
blood pressure [55–59,66], would be expected to show different results as bradycardic/hypotensive
subjects are less acidotic, and may have a less compromised vascular tone. These limitations make the
interpretation of data challenging. Epinephrine administration is not without risk; knowing when and
if epinephrine may be beneficial with newborn resuscitation remains to be determined.
Focusing on studies in which animals were asphyxiated to cardiac arrest, Berg et al. have
shown that 7/10 piglets in the chest compression and ventilation group achieved ROSC by the end
of an 8-minute period of bystander CPR prior to any epinephrine administration [67]. In a study
by McNamara et al. comparing a single dose of vasopressin (high or low dose –HDV, LDV) and
epinephrine (high [0.03 mg/kg] or low [0.01 mg/kg] dose –HDE, LDE) to saline (control), 9/65 (14%)
piglets achieved ROSC with the initiation of CPR prior to the administration of the study drug. In the
remaining 56 piglets analyzed, the success of ROSC was similar in the control (5/12 or 42%) and
the LDE group (5/13 or 39%), while HDE achieved ROSC in 6/11 (55%) piglets [56]. In perinatal
asphyxial cardiac arrest lamb models comparing 3:1 compression-to-ventilation CPR and continuous
chest compressions during sustained inflations, the first dose of epinephrine was administered at
6 min [68]. 6/13 lambs achieved ROSC without epinephrine in a median (IQR) time of 210 (185–230)
sec, while in the seven lambs that received epinephrine, ROSC was achieved in a median (IQR) time
of 60 (45–130) sec following epinephrine administration [68]. This time to ROSC from epinephrine
administration was comparable to another study in a similar model, where the median (IQR) time
to ROSC following IV epinephrine was 90 (70–140) sec [38]. Collectively, results from this series of
studies suggest that while not all asphyxiated cardiac arrested animal models require epinephrine to
achieve ROSC, administration of epinephrine appears to hasten ROSC.
Epinephrine administration has been shown to increase mean arterial pressure and carotid blood
flow in asphyxiated bradycardic newborn lambs [66]. The hemodynamic effects of epinephrine
during chest compressions in asphyxial cardiac arrest, however, do not corroborate these findings.
Hemodynamic data during chest compression in perinatal asphyxiated newborn lambs did not
demonstrate any significant increase in diastolic or systolic blood pressures, and no increase in carotid
blood flow following epinephrine administration [38,69]. One possible explanation for the lack of
effect on hemodynamics with epinephrine administration in this model may be due to the depletion of
adenosine triphosphate during asphyxia, which is required to maintain vascular tone.
In the absence of positive hemodynamic effects from epinephrine administration in the severely
asphyxiated neonate, repeat epinephrine doses may potentiate adverse effects. Pharmacokinetic data
has shown that repeated intravenous epinephrine administration (0.03 mg/kg) results in a cumulative
increase in plasma epinephrine concentrations that can exceed 1000 ng/mL after four doses [38].
Also, very high plasma epinephrine concentrations (>700 ng/mL) were observed following ROSC
in lambs that received repeated doses of ETT epinephrine. These data suggest that epinephrine
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administered into the lungs is not well absorbed during resuscitation. The lungs can function as a
depot until pulmonary blood flow increases upon ROSC resulting in a sharp rise in epinephrine plasma
concentrations. Repeated epinephrine doses were associated with a higher risk of tachyarrhythmia.
Interestingly, in McNamara et al.’s study, piglets that were randomized to receive low dose epinephrine
were noted to have more frequent VF on echocardiogram, and required a greater number of shocks
and higher joules [56].
4. Epinephrine Flush Volume
The current NRP guidelines recommend a 0.5–1.0 mL normal saline flush following epinephrine
administration from a low lying UVC [24]. It is unclear whether this volume is sufficient to propel
epinephrine from the umbilical vein into the right atrium to reach the circulation and may deposit
most of the drug in the umbilical vein and liver (Figure 6). In a perinatal asphyxiated cardiac arrest
lamb model, subjects were randomized to receive a (1) low-volume 1 mL normal saline flush or (2)
high-volume 10 mL (approximately 3 mL/kg) normal saline flush following administration of IV
epinephrine, 0.03 mg/kg [70]. Lambs that received a high-volume flush had 100% ROSC success (3/3
lambs) following the first dose of epinephrine compared to 33% ROSC in lambs who were given a
low-flush volume (1/3 lambs; p > 0.05). In addition, the median time (IQR) to ROSC was shorter
in the high-volume flush at 40 sec (35–50 s) compared to 48 sec (42–54 s) in the low-volume flush
(p > 0.05) [70].
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5. Alternate edication in Neonatal Resuscitation
Given the potential adverse effects of epinephrine and that epinephrine is the only recommended
vasoactive drug to be administered during bradycardia or asystole by NRP, there is great interest
in finding alternative vasoconstrictors to be used during neonatal resuscitation. Vasopressin was
first proposed as a resuscitation agent after endogenous vasopressin concentrations were found to
be higher in successfully resuscitated patients compared with those who died [71]. The evidence for
vasopressin use in cardiac arrest, however, has been contentious. Animal experimental models in
cardiac arrest have demonstrated improved survival after vasopressin administration compared to
epinephrine [72–75], though clinical trials have not demonstrated improved outcomes and the use
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of vasopressin is currently not recommended for pediatric or adult cardiac arrest [28,41]. Unlike
epinephrine, vasopressin is not a direct myocardial stimulant and does not significantly increase
myocardial oxygen demand. In Mcnamara and colleagues’ study in asphyxiated newborn piglets,
vasopressin was shown to improve survival, lower post-resuscitation troponin, and less hemodynamic
compromise compared to epinephrine [56]. In contrast, in a perinatal asphyxiated cardiac arrest lamb
model, vasopressin (0.4 U/kg IV) compared to epinephrine (0.03 mg/kg IV resulted) resulted in a lower
incidence of ROSC (3/9 vs. 7/10, respectively), as well as a longer time to achieve ROSC (13 ± 6 min
vs. 8 ± 2 min, respectively). Furthermore, vasopressin caused coronary vasoconstriction (37 ± 44 g/g),
whereas epinephrine dilated coronary arterial rings (−16± 12 g/g, p< 0.05). A vasoconstriction response
to epinephrine was higher compared to vasopressin in carotid (162 ± 64 vs. 49 ± 52 g/g, p = 0.02) and
pulmonary arterial rings (19 ± 6 vs. 4 ± 9g/g, p = 0.01) [76]. Clinical studies with neurodevelopmental
follow-up comparing epinephrine and vasopressin during neonatal resuscitation is warranted.
6. Conclusions
In an era fueled by scientific research that is growing at an exponential rate, we strive to assimilate
the vast evidence available to provide the best care to our patients. In the field of neonatal resuscitation,
particularly pertaining to optimizing CPR and drug delivery in the most severely asphyxiated newborns,
there remain important gaps in knowledge that remain to be addressed. The infrequent need for
aggressive resuscitation in newborns has prevented the execution of large randomized clinical trials.
As a result, the current recommendations are extrapolated from adult, animal or manikin studies
that do not adequately represent the transitioning circulation and fluid-filled lungs characteristic of
newborns. A novel perinatal asphyxial cardiac arrest newborn lamb model has provided new evidence
on the pharmacokinetics and hemodynamics of epinephrine during neonatal resuscitation. Future
studies assessing physiologic parameters (including coronary and ductal blood flow) of variable doses
and routes (IO, intramuscular) of vasoactive drug administration will provide critical insights to further
advance the field of neonatal resuscitative medicine.
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